Silje Johansen1, Ingvild Jenssen Laegreid2, Siw Leiknes Ernstsen2, Nessar Ahmad Azrakhsh1, Astrid Olsnes Kittang1,3, Roald Lindås1, Bjørn Tore Gjertsen1,3, Nils Vetti4,5, Trude Victoria Mørtberg2,6, Ingvild Hausberg Sørvoll2, Pål André Holme7,8, Maria Therese Ahlen2, Håkon Reikvam1,3. 1. Section of Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway. 2. The Norwegian National Unit for Platelet Immunology, Division of Diagnostics, University Hospital of North Norway, Tromsø, Norway. 3. Department of Clinical Science, University of Bergen, Bergen, Norway. 4. Department of Radiology, Haukeland University Hospital, Bergen, Norway. 5. Department of Medical Science, University of Bergen, Bergen, Norway. 6. Institute of Medical Biology, University of Tromsø - The Arctic University of Norway, Tromsø, Norway. 7. Department of Hematology, Oslo University Hospital, Norway. 8. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.
Abstract
BACKGROUND: Vaccine-induced immune thrombotic thrombocytopenia (VITT) has so far only been reported after adenovirus vector severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. OBJECTIVE: We report findings in a 25-year-old woman who presented with thrombocytopenia, venous thrombosis, elevated D-dimer levels, and high levels of platelet-activating antibodies to platelet factor 4-polyanion complexes 10 days after Gardasil 9 vaccination for human papillomavirus (HPV). The patient exhibited clinical and laboratory features in line with the recently defined VITT syndrome, described after adenoviral vector vaccination to prevent coronavirus disease 2019. CONCLUSION: We report a case of VITT following HPV vaccination. This should raise awareness of the possibility of VITT also occurring after other vaccines, not exclusively adenoviral vector-based SARS-CoV-2 vaccines.
BACKGROUND: Vaccine-induced immune thrombotic thrombocytopenia (VITT) has so far only been reported after adenovirus vector severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. OBJECTIVE: We report findings in a 25-year-old woman who presented with thrombocytopenia, venous thrombosis, elevated D-dimer levels, and high levels of platelet-activating antibodies to platelet factor 4-polyanion complexes 10 days after Gardasil 9 vaccination for human papillomavirus (HPV). The patient exhibited clinical and laboratory features in line with the recently defined VITT syndrome, described after adenoviral vector vaccination to prevent coronavirus disease 2019. CONCLUSION: We report a case of VITT following HPV vaccination. This should raise awareness of the possibility of VITT also occurring after other vaccines, not exclusively adenoviral vector-based SARS-CoV-2 vaccines.
Authors: María Eva Mingot-Castellano; Nora Butta; Mariana Canaro; María Del Carmen Gómez Del Castillo Solano; Blanca Sánchez-González; Reyes Jiménez-Bárcenas; Cristina Pascual-Izquierdo; Gonzalo Caballero-Navarro; Laura Entrena Ureña; Tomás José González-López Journal: Vaccines (Basel) Date: 2022-06-16